91. バッド・キアリ症候群 Budd-Chiari syndrome Clinical trials / Disease details


臨床試験数 : 4 薬物数 : 5 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 14

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100046725
2022-01-012021-05-27The efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplastyTo compare the efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty Budd-Chiari syndromeWarfarin group:oral take Warfarin;Rivaroxaban group:oral take rivaroxaban;The First Affiliated Hospital of Zhengzhou UniversityNULLRecruiting1875BothWarfarin group:40;Rivaroxaban group:40;N/AChina
2EUCTR2014-005162-29-NL
(EUCTR)
09/04/202013/06/2019Treatment of thrombosis in the abdominal veinsTreatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study - RIVASVT100 Splanchnic vein thrombosis (SVT) is an unusual site manifestation of venous thromboembolism (VTE). It includes the Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), mesenteric vein thrombosis (MVT) and splenic vein thrombosis (spVT). PVT is the most frequent manifestation of SVT, followed by MVT. ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: rivaroxaban 20 mg
Product Name: rivaroxaban
University of InsubriaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 4France;Canada;Germany;Netherlands;Italy